GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTED-UPDATE 2-Indonesia turns to China to help plug vaccine shortage after AstraZeneca delays

Thu, 08th Apr 2021 06:41

(Changes day in first paragraph from Wednesday to Thursday)

By Stanley Widianto

JAKARTA, April 8 (Reuters) - Indonesia is in talks with
China on getting as many as 100 million COVID-19 vaccine doses
to plug a gap in deliveries after delays in the arrivals of
AstraZeneca shots, Health Minister Budi Gunadi Sadikin said on
Thursday.

He told a parliamentary hearing that Indonesia would receive
20 million doses of the AstraZeneca vaccine via a bilateral deal
in 2021, instead of 50 million doses initially agreed.

The remaining 30 million doses were due to be shipped by the
second quarter of 2022, he said.

Budi said the government had "embarked on a discussion with
the Chinese government to ask for an additional 90-100 million
(doses)".

"We're also asking for vaccines from the U.S. when they're
done with their own vaccinations and sell their vaccines
overseas."

Besides AstraZeneca, Indonesia relies heavily on vaccines
produced by China's Sinovac Biotech for coronavirus
inoculations which began in January. It aims to reach 181.5
million people within a year in a bid to reach herd immunity.

Sinovac has supplied about 56 million doses so far.

Indonesia was also slated to receive 54 million doses of the
AstraZeneca vaccine in phases via the COVAX sharing scheme,
though Budi said Indian export restrictions would delay
shipments in April.

"That's something that we cannot accept and we're
negotiating with AstraZeneca. So that's 100 million doses of
vaccine whose schedule remains unclear," he said.

AstraZeneca did not immediately respond to a request for
comment.

Indonesia has also launched a private vaccination programme
to allow companies to buy government-procured vaccines and
inoculate staff for free.

State-owned company Bio Farma had started negotiations with
China's Sinopharm and Cansino, along with the producer of
Russia's Sputnik V, for vaccines for the private programme, Bio
Farma chief executive Honesti Basyir told the parliamentary
hearing.

The Southeast Asian country has been struggling to control
one of Asia's worst epidemics, having reported more than 1.54
million coronavirus cases and 42,000 deaths as of Wednesday.

Indonesia has administered at least one vaccine shot to more
than 9.22 million people.

European and British regulators said on Wednesday they had
found possible links between AstraZeneca's vaccine and very rare
cases of blood clots, but reaffirmed its importance in
protecting people against COVID-19.
(Additional Reporting by Nilufar Rizki
Editing by Ed Davies and Nick Macfie)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.